Jain Global LLC Makes New Investment in Xenon Pharmaceuticals Inc. $XENE

Jain Global LLC bought a new position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 252,379 shares of the biopharmaceutical company’s stock, valued at approximately $10,133,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Aster Capital Management DIFC Ltd acquired a new position in shares of Xenon Pharmaceuticals during the third quarter worth about $39,000. Elevation Point Wealth Partners LLC acquired a new stake in Xenon Pharmaceuticals in the second quarter valued at about $32,000. State of Wyoming lifted its position in Xenon Pharmaceuticals by 112.8% in the third quarter. State of Wyoming now owns 1,151 shares of the biopharmaceutical company’s stock valued at $46,000 after purchasing an additional 610 shares during the period. Osaic Holdings Inc. boosted its holdings in Xenon Pharmaceuticals by 541.4% in the 2nd quarter. Osaic Holdings Inc. now owns 1,225 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 1,034 shares in the last quarter. Finally, L1 Capital Pty Ltd purchased a new stake in Xenon Pharmaceuticals in the 2nd quarter valued at approximately $41,000. Hedge funds and other institutional investors own 95.45% of the company’s stock.

Xenon Pharmaceuticals Trading Down 1.0%

XENE stock opened at $54.66 on Tuesday. The firm has a 50 day moving average of $43.97 and a 200-day moving average of $42.07. The company has a market cap of $4.55 billion, a price-to-earnings ratio of -12.54 and a beta of 0.91. Xenon Pharmaceuticals Inc. has a 12-month low of $26.74 and a 12-month high of $63.95.

Xenon Pharmaceuticals (NASDAQ:XENE) last released its quarterly earnings results on Thursday, February 26th. The biopharmaceutical company reported ($1.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.11). During the same period last year, the business posted ($0.84) earnings per share. Sell-side analysts forecast that Xenon Pharmaceuticals Inc. will post -3.1 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CEO Ian Mortimer sold 270,000 shares of the firm’s stock in a transaction on Monday, March 9th. The stock was sold at an average price of $60.33, for a total value of $16,289,100.00. Following the completion of the transaction, the chief executive officer owned 6,000 shares in the company, valued at $361,980. This trade represents a 97.83% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Andrea Difabio sold 2,607 shares of Xenon Pharmaceuticals stock in a transaction on Tuesday, March 10th. The stock was sold at an average price of $60.11, for a total value of $156,706.77. Following the transaction, the insider directly owned 4,893 shares of the company’s stock, valued at $294,118.23. This trade represents a 34.76% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 336,707 shares of company stock valued at $19,622,565. 4.07% of the stock is owned by insiders.

Wall Street Analyst Weigh In

XENE has been the subject of a number of analyst reports. Deutsche Bank Aktiengesellschaft increased their target price on Xenon Pharmaceuticals from $56.00 to $90.00 and gave the stock a “buy” rating in a research note on Tuesday, March 10th. HC Wainwright lifted their price target on Xenon Pharmaceuticals from $53.00 to $74.00 and gave the company a “buy” rating in a research note on Tuesday, March 10th. Jefferies Financial Group set a $100.00 price objective on Xenon Pharmaceuticals in a report on Monday, March 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a research report on Friday, January 9th. Finally, Wells Fargo & Company raised their target price on Xenon Pharmaceuticals from $49.00 to $68.00 and gave the company an “overweight” rating in a report on Tuesday, March 10th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $71.88.

Xenon Pharmaceuticals Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.